Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

1(33.3%)

Phase 2

1(33.3%)

N/A

1(33.3%)

3Total

Phase 4(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05845593Recruiting

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)

Role: lead

NCT03142711Completed

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus

Role: collaborator

NCT03626311Not ApplicableCompleted

Omega-3 Replacement With Krill Oil in Disease Management of SLE

Role: collaborator

NCT02598596Phase 2Completed

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

Role: lead

NCT03098823Phase 4Completed

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

Role: lead

All 5 trials loaded